Skip to main content Accessibility help
×
Home

Oral squamous cell carcinoma and serum paraoxonase 1

  • Z Boy Metin (a1), S Aydin (a2), M Unur (a1), B Cakmakoglu (a3), B Toptas (a3), G Hafiz (a4) and T İsbir (a3)...

Abstract

Background:

Serum paraoxonase 1 is involved in mechanisms that protect cells from oxidative stress damage. This study aimed to investigate the correlation between serum paraoxonase 1 activity and polymorphisms in patients with oral squamous cell carcinoma.

Methods and materials:

Fifty-seven patients with oral squamous cell carcinoma and 59 matched healthy controls participated in the study. Serum paraoxonase 1 activity and polymorphisms in blood samples were compared with results for polymerase chain reaction and restriction fragment length polymorphism tests.

Results:

Mean serum paraoxonase 1 activity levels were lower in patients than controls (mean ± standard deviation, 21.9 ± 5 units/l and 120.4 ± 2 units/l, respectively) (p = 0.001). The serum paraoxonase 1 192 glutamine polymorphism was more common in patients than controls.

Conclusion:

Patients with oral squamous cell carcinoma had significantly lower serum paraoxonase 1 activity levels and a greater prevalence of the serum paraoxonase 1 192 glutamine allele, compared with controls. Serum paraoxonase 1 may play a role in the aetiology of oral squamous cell carcinoma.

Copyright

Corresponding author

Address for correspondence: Dr Salih Aydın, Bağcilar Eğitim Araştirma Hastanesi, Kulak Burun Boğaz Kliniği, Bağcilar, Istanbul, Turkey43200 E-mail: drsalihaydin@gmail.com

References

Hide All
1Poh, CF, MacAulay, CE, Laronde, DM, Williams, PM, Zhang, L, Rosin, MP. Squamous cell carcinoma and precursor lesions: diagnosis and screening in a technical era. Periodontol 2000 2011;57:7388
2Hoffman, HT, Karnell, LH, Funk, GF. The national cancer database report on cancer of head and neck. Arch Otolaryngol Head Neck Surg 1998;124:951–62
3Funk, GF, Karnell, LH, Robinson, RA, Zhen, WK, Trask, DK, Hoffman, HT. Presentation, treatment, and outcome of oral cavity cancer: a national cancer data base report. Head Neck 2002;24:165–80
4Da Silva, SD, Ferlito, A, Takes, RP, Brakenhoff, RH, Valentin, MD, Woolgar, JA et al. Advances and applications of oral cancer basic research. Oral Oncol 2011;47:783–91
5Sun, Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 1990;8:583–99
6Fang, DH, Fan, CH, Ji, Q, Qi, BX, Li, J, Wang, L. Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol Biol Rep 2012;39:6801–9
7Patel, BP, Rawal, UM, Dave, TK, Rawal, RM, Shukla, SN, Shah, PM. Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. PS Integr Cancer Ther 2007;6:365–72
8Manoharan, S, Kolanjiappan, K, Suresh, K, Panjamurthy, K. Lipid peroxidation and antioxidant status in patients with oral squamous cell carcinoma. Indian J Med Res 2005;122:529–34
9Subapriya, R, Kumaraguruparan, R, Ramachandran, CR, Nagini, S. Oxidant antioxidant status in patients with oral squamous cell carcinomas at different intraoral sites. Clin Biochem 2002;35:489–93
10Manoharan, S, Baskar, AA, Manivasagam, T, Subramanian, P. Circadian rhythmicity of plasma lipid peroxidation and antioxidants in oral squamous cell carcinoma. Singapore Med J 2005;46:184–8
11Martínez, C, Molina, JA, Alonso-Navarro, H, Jiménez-Jiménez, FJ, Agúndez, JA, García-Martín, E. Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol 2010;10:71
12Costa, LG, Giordano, G, Furlong, CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011;81:337–44
13De Roos, AJ, Gold, LS, Wang, S, Hartge, P, Cerhan, JR, Cozen, W et al. Metabolic gene variants and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2006;15:1647–53
14Lincz, LF, Kerridge, I, Scorgie, FE, Bailey, M, Enno, A, Spencer, A. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 2004;89:628–9
15Krzystek-Korpacka, M, Boehm, D, Matusiewicz, M, Diakowska, D, Grabowski, K, Gamian, A. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes – connection with inflammation. Clin Biochem 2008;41:804–11
16Camuzcuoglu, H, Arioz, DT, Toy, H, Kurt, S, Celik, H, Erel, O. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol 2009;112:481–5
17Antognelli, C, Mearini, L, Talesa, VN, Giannantoni, A, Mearini, E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005;63:240–51
18Akcay, MN, Polat, MF, Yilmaz, I, Akcay, G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003;50:225–7
19Akcay, MN, Yilmaz, I, Polat, MF, Akcay, G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003;50:273–5
20Lee, CH, Lee, KY, Choe, KH, Hong, YC, Kim, YD, Kang, JW et al. Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Public Health 2005;38:345–50
21Stevens, VL, Rodriguez, C, Pavluck, AL, Thun, MJ, Calle, EE. Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2006;15:1226–8
22Miller, SA, Dykes, DD, Polesky, HS. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988;16:1215
23Adkins, S, Gan, KN, Mody, M, La Du, BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598608
24Humbert, R, Adler, DA, Disteche, CM, Hassett, C, Omiecinski, CJ, Furlong, CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993;3:73–6
25Furlong, CE, Richter, RJ, Seidel, SL, Costa, LG, Motulsky, AG. Spectrophotometric assay for the enzymatic hydrolysis of the active metabolites of chlorpyrites and parathion by plasma paraoxonase/arylesterase. Anal Biochemistry 1989;180:242–7
26Klaunig, JE, Kamendulis, LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239–67
27Van Der Logt, EM, Janssen, CH, Van Hooijdonk, Z, Roelofs, HM, Wobbes, T, Nagengast, FM et al. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res 2005;25:1465–70
28Lurie, G, Wilkens, LR, Thompson, PJ, McDuffie, KE, Carney, ME, Terada, KY et al. Genetic polymorphisms in the paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 2008;17:2070–7
29Costa, LG, Vitalone, A, Cole, TB, Furlong, CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;15;69:541–50
30Elkiran, ET, Mar, N, Aygen, B, Gursu, F, Karaoglu, A, Koca, S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48

Keywords

Oral squamous cell carcinoma and serum paraoxonase 1

  • Z Boy Metin (a1), S Aydin (a2), M Unur (a1), B Cakmakoglu (a3), B Toptas (a3), G Hafiz (a4) and T İsbir (a3)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed